Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CABOREAL
- Sponsors Ipsen
- 24 Jul 2019 Status changed from recruiting to completed.
- 29 May 2019 Planned End Date changed from 10 Jun 2019 to 15 Jul 2019.
- 29 May 2019 Planned primary completion date changed from 15 Apr 2019 to 7 Jun 2019.